Medication-related osteonecrosis of the jaw (MRONJ) is a rare but serious complication that can damage the jawbone. It can occur after treatments like pulling a tooth or treating severe gum disease. It affects some people who are taking or have taken medications to protect bones.

Medication-related osteonecrosis of the jaw (MON, MRONJ) is progressive death of the jawbone in a person exposed to a medication known to increase the risk of disease, in the absence of a previous radiation treatment.

Apr 11, 2023 · Medication-related osteonecrosis of the jaw (MRONJ) is a rare but serious adverse effect of bone antiresorptive agents (i.e., bisphosphonates, denosumab) used for osteoporosis. Patients at increased risk of MRONJ include those:

Medication-related osteonecrosis of the jaw (MRONJ) is a major problem that can occur in people taking certain medications such bisphosphonates and denosumab. It can be used to treat osteoporosis or cancer.

Medication-related osteonecrosis of the jaw (MRONJ) is a rare, severe debilitating condition from unknown causes. It is characterized by nonhealing exposed bone in a patient with a history of antiresorptive or antiangiogenic agents in the absence of …

Medication-related osteonecrosis of the jaw (MRONJ) is a severe adverse drug reaction, consisting of progressive bone destruction in the maxillofacial region of patients. ONJ can be caused by two pharmacological agents: Antiresorptive (including bisphosphonates (BPs) and receptor activator of nuclear factor kappa-B ligand inhibitors) and ...

Medication-related osteonecrosis of the jaw (MRONJ) is a rare but serious complication from antiresorptive and antiangiogenic therapy, causing progressive bone destruction in the maxillofacial region. 1 Patients can present with multiple oral complaints impacting negatively on their quality of life. 2 The first cases of osteonecrosis of the jaw ...

Medication-related osteonecrosis of the jaw (MRONJ) is a rare and potentially debilitating dental emergency. MRONJ is characterized by nonhealing exposed bone in patients with a history or ongoing use of bisphosphonates (particularly administered via high-dose IV) and other antiresorptive agents (eg, denosumab ), or an antiangiogenic agent and ...

There is an increased risk of oral health complications for patients prescribed anti-resorptive or anti-angiogenic drugs (medication-related osteonecrosis of the jaw, MRONJ).

Feb 3, 2020 · Case Definition of MRONJ. According to the American Association of Oral and Maxillofacial Surgeons, patients may be considered to have MRONJ if the following characteristics are present: Current or previous treatment with antiresorptive or …